# Cerapedics Inc.

> Cerapedics is a commercial-stage ortho-biologics company that engineered a synthetic 15-amino-acid peptide, P-15, to coax the body into building bone faster. Its FDA-approved i-FACTOR is used in cervical spine fusions, and its 2025 PearlMatrix approval made it the first and only proven bone growth accelerator cleared for lumbar fusion.

- **Founded:** 2001
- **Headquarters:** Westminster, Colorado, United States
- **Founders:** Andrew Tofe (Founder, Ph.D. (nuclear scientist who licensed P-15 from UCSF))
- **Team size:** ~230 employees
- **Products:** i-FACTOR Peptide Enhanced Bone Graft, PearlMatrix P-15 Peptide Enhanced Bone Graft, P-15 Technology Platform
- **Notable:** FDA PMA approval of i-FACTOR for cervical spine fusion (2015), FDA Breakthrough Device designation for PearlMatrix (April 2021), FDA PMA approval of PearlMatrix for lumbar TLIF (June 2025) - first and only proven bone growth accelerator for lumbar fusion

## Products & services

- **i-FACTOR Peptide Enhanced Bone Graft** — FDA-PMA approved (2015) bone graft for single-level anterior cervical discectomy and fusion (ACDF). Combines P-15 peptide with anorganic bone mineral.
- **PearlMatrix P-15 Peptide Enhanced Bone Graft** — FDA-PMA approved (2025) drug-device combination for single-level transforaminal lumbar interbody fusion (TLIF). The first and only proven bone growth accelerator for the lumbar spine. Granted Breakthrough Device designation in April 2021.
- **P-15 Technology Platform** — Proprietary 15-amino-acid synthetic peptide that mimics the cell-binding site of Type-I collagen, activating osteogenic cell attachment, migration, and differentiation.

## Achievements

- FDA PMA approval of i-FACTOR for cervical spine fusion (2015)
- FDA Breakthrough Device designation for PearlMatrix (April 2021)
- FDA PMA approval of PearlMatrix for lumbar TLIF (June 2025) - first and only proven bone growth accelerator for lumbar fusion
- P-15 peptide platform used clinically in dentistry since 2000
- Multi-center pivotal trials with long-term safety and efficacy data

## Latest updates

- **2025-06** — FDA PMA approval of PearlMatrix P-15 Peptide Enhanced Bone Graft for single-level TLIF.
- **2024-09** — Expanded indications for use approved for i-FACTOR P-15.
- **2023-07** — Expanded Westminster headquarters to accommodate additional manufacturing and R&D.
- **2022-03** — Raised $25M venture round.
- **2021-04** — PearlMatrix granted FDA Breakthrough Device designation.

## Links

- Website: https://cerapedics.com
- LinkedIn: https://www.linkedin.com/company/cerapedics
- Twitter/X: https://twitter.com/CerapedicsInc
- YouTube: https://www.youtube.com/@cerapedics
- Facebook: https://facebook.com/Cerapedics/

---

Profile page: https://yespress.io/cerapedics-inc
Published by YesPress — https://yespress.io
Last updated: 2026-05-19